17
PGX CDS PROCESS OUTCOMES Tim Herr Northwestern University

PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Embed Size (px)

Citation preview

Page 1: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

PGX CDSPROCESS OUTCOMESTim Herr

Northwestern University

Page 2: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Goals

•Primary:• Determine how PGx CDS alerts affect clinical action

• Intermediate:• Inventory of alert scenarios across sites• Understand rates at which alerts are firing• Determine how physicians interact with alerts

Page 3: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Data Collection• Data submission templates

Page 4: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Alert Scenarios

Page 5: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Example Alert Scenarios: Warfarin• Marshfield: WARFARIN_2_2_AA

• “Genetic testing for this individual (CYP2C9*2/*2 and VKORC1: AA) indicates an initial Warfarin dose of 0.5 mg - 2 mg may be considered.”

• Mayo: warfarin/CYP2C9/VKORC1_dose_calculator• “An alert/calculator is generated for new warfarin orders if patient has

CYP2C9 and VKORC1 results in the EMR. The alert/calculator displays the variables used and the calculated dose.”

• Northwestern: Warfarin (Not on Medication, Prescribing) • “Dosing calculator should be used to determine initial warfarin dose.

Enter clinical data into dosing calculator for all patients. Addition of genetic information (see lab results) suggested for non-African Americans.”

Page 6: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Example Alert Scenarios: Clopidogrel• Mt. Sinai: Clopidogrel-CYP2C19 IM

• “Change to either Prasugrel or Ticagrelor”

• Marshfield: CLOPIDOGREL_2_17• “Consider alternative antiplatelet therapy.”

• Northwestern: Clopidogrel Intermediate Metabolizer (Prescribing)• “Consider alternative - medication may be ineffective if prescribed.”

Page 7: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Provider Information

Page 8: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Alert Instances

Page 9: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Alert Response vs. Clinical Response

Accept

Override

Ignore

Followed

Not Followed

No Action

Alert Response Clinical Response

Page 10: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Alerts Submitted

Organization Number of Alerts

Boston Children’s 0 (No production alerts fired)

Cincinnati Children’s 22

Marshfield Clinic 12

Mayo Clinic 5

Mt. Sinai 2

Northwestern 36 (5 active; 31 passive)

Vanderbilt 143

Total 220

Page 11: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Alerts by Drug-Gene Interaction

Page 12: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Alert Responses

Page 13: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Clinical Responses

Page 14: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Responses by DGI

DGI # Alerts Accept Followclopidogrel 171 32 10simvastatin 19 15 12warfarin 7 0 1

Page 15: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

An Interesting Story…

• Alert: 12294605• SIMVASTATIN METABOLISM-INTERMEDIATE ACTIVITY (NOT ON MED)

• Patient had been on simvastatin 40mg for several years but Rx was expired or discontinued

• Physician sees alert at order entry• Physician opens SmartSet (informational materials)

• Physician orders simvastatin 40 mg, anyway

Page 16: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

An Interesting Story…

• Approx. three weeks later...• Alert: 12501097• SIMVASTATIN METABOLISM-INTERMEDIATE ACTIVITY

• Physician #2 sees alert in General BPAs section

• Physician #2 opens SmartSet (informational materials)

• Physician #2 orders atorvastatin 20mg

Page 17: PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Questions?

• Acknowledgements:• The PGx Process Outcomes Workgroup• Especially Luke Rasmussen and Josh Peterson